Cost-Effectiveness Of Blinatumomab Versus Standard Of Care In Adult Patients With Philadelphia-Chromosome-Negative B-Precursor Acute Lymphoblastic Leukemia In First Hematological Complete Remission (Cr) With Minimal Residual Disease (Mrd) From A Us Payer Perspective

BLOOD（2018）

引用 0|浏览0

暂无评分

摘要

INTRODUCTION:

查看译文

关键词

acute lymphoblastic leukemia,lymphoblastic leukemia,blinatumomab versus standard,cost-effectiveness,philadelphia-chromosome-negative,b-precursor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要